What Globalpharma does

Globalpharma Co. (L.L.C.) is a Dubai-based generic pharmaceutical manufacturer founded in 1998 and headquartered at Dubai Investment Park. It operates a 27,000 m2 cGMP-certified manufacturing complex comprising a dedicated Beta-Lactam Penicillin plant (producing Amoxicillin and AmoxiClav under the Gloclav and Glomox brands) and a General Medicine plant with annual capacity of 300 million tablets, 150 million capsules, and over 3 million litres of dry suspension and liquid. The portfolio has grown from 2 products at inception to more than 90 SKUs spanning anti-infectives, cardiovascular, anti-diabetics, anti-ulcerants, NSAIDs and analgesics, respiratory, antihistamines, vitamins and supplements, and herbal medicines (MG21, CG21). Recent additions include EU-certified Oral Disposible Film (ODF) technology licensed from ZIM Laboratories (India) in April 2025 and 25 new product launches planned for 2025.

The company sells through a B2B pharmaceutical distribution model targeting major hospitals, chain pharmacy groups, and government health authorities across 14+ countries in the GCC, broader Middle East, Africa, and CIS. Key channel partners include Wasfaty in Saudi Arabia — a major driver of the 139.5% year-over-year Saudi sales growth to $12.6M by May 2024 — and Alphamed for UAE herbal distribution. Trailing twelve months sales (June 2023 to May 2024) reached $70.3M, up 44.7% year-over-year, with first-five-months 2024 sales of $33.2M representing 78.6% growth. Pricing is quote-based, set through tenders and distributor agreements; the company is privately held as a wholly-owned subsidiary of Dubai Investments PJSC, a publicly listed diversified group on the Dubai Financial Market.

Name

Globalpharma

Legal name

GLOBALPHARMA CO. (L.L.C.)

Website

https://globalpharma.ae

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Specialty Pharmaceutical Distributors (HLAIAJAB), Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF), Vitamins & Minerals (Single Nutrients) (CRADAGAB), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Beta-lactam antibiotics
• Herbal medicines
• Oral dispersible films

Headquarters

HQ city

Dubai

HQ country

United Arab Emirates

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Product Sales: Manufacturing and commercializing generic pharmaceutical products across multiple therapeutic segments including antibiotics, cardiovascular, anti-ulcerants, analgesics, NSAIDs, food supplements, vitamins, anti-diabetics, respiratory products, and anti-histamine formulations. Revenue generated through product sales to distributors, hospitals, and pharmacies across GCC, Middle East, and African markets.
2. Herbal Medicines Distribution: Distribution of herbal medicines including MG21 through Alphamed distribution agreement across Middle East pharmacies.
3. Consumer Health Products (GP+ Brand): Manufacturing and distribution of consumer health products including hand sanitizers and face masks under the GP+ brand during and post-pandemic.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

Globalpharma manufactures and commercializes generic pharmaceutical products across multiple therapeutic segments including anti-infectives, cardio-metabolic, NSAIDs/pain killers, anti-ulcerants, anti-diabetics, respiratory, anti-histamine, vitamins, and herbal medicines. The company operates cGMP-certified manufacturing facilities in Dubai Investment Park covering 27,000 m2 with annual capacity of 300 million tablets, 150 million capsules, and over 7 million litres of dry syrup and liquid, producing more than 90 products sold across 14+ countries in the GCC, Middle East, and African markets.

Product overview

Globalpharma is a pharmaceutical manufacturer specializing in generic medicines, established in 1998 and headquartered in Dubai Investments Park. The company operates two state-of-the-art manufacturing plants: a Beta-Lactam Penicillin Manufacturing plant providing Amoxicillin & AmoxiClav brands (Gloclav, Glomox) and a General Medicine Manufacturing Plant with Liquid & Oral Solid Dose capabilities. Globalpharma manufactures and distributes more than 90 products across lifestyle disease segments including Cardiovasculars (Sartan, Irvel, Atorlip, Rosuvastatin, RUSET, Glovadip), Anti-ulcerants (Emilok), Anti-Diabetics (Emivanz, Emipride), Anti-Arthritis/Analgesics including NSAIDs (Emifenac DT, Emidol, Emifen, Algoxib), Respiratory, Anti-histamine formulations (Glozal, Emilora, Glotrizine, Gloditen, EzeAir), Anti-infectives (Gloclav, Glomox, Emicipro, Emimycin, Levotab), and Multivitamin supplements (Glovit family). The company also produces herbal medicines including MG21 and CG21, and consumer health products like GP+ sanitizers and face masks. All manufacturing facilities are cGMP certified and approved by health authorities across GCC, UAE, Saudi FDA, Levant, Africa, and CIS regions.

Differentiator

Problem solved

Functional benefit

Brands

• GP+: Hand sanitizer and facemask brand launched in 2020 during COVID-19 pandemic. GP+ hand sanitizers are approved by Dubai Municipality and manufactured per WHO guidelines with 75% Isopropyl alcohol, available in 100ml and 250ml spray bottles.
• MG21
• CG21

Products and services

• Gloclav (Amoxicillin + Clavulanate Potassium) Beta-lactam penicillin antibiotic available in tablet and oral suspension forms for treating bacterial infections. Flagship brand providing Amoxicillin & AmoxiClav in the larger MENA region.
• Glomox (Amoxicillin) Amoxicillin antibiotic available in capsules, tablets and oral suspension forms for treating various bacterial infections.
• Emifenac DT (Diclofenac Dispersible) Diclofenac dispersible tablet for pain and inflammation management. One of the company's well-respected brands across Middle East & North African markets.
• Emidol (Paracetamol) Paracetamol analgesic available in tablets, syrup and suspension forms for pain and fever relief.
• Glovit Softgels (Multivitamin) Multivitamin supplement brand trusted by healthcare professionals for quality and proven efficacy, part of the multivitamin range.
• MG21 Herbal Medicine Herbal anti-inflammatory medicine consisting of pure extract of Myrrh and Costus, used for treatment and prevention of respiratory infections, indigestion, skin infections, headaches and diabetic conditions. First herbal product manufactured at the company's MOHAP-approved herbal manufacturing line.
• CG21 Herbal Medicine Herbal anti-inflammatory medicine inspired by UAE heritage, incorporating a distinctive formulation blending Cloves and Costus, succeeding MG21.
• RUSET (Rosuvastatin + Ezetimibe) Combination lipid-lowering medication with Rosuvastatin and Ezetimibe, available in four distinct SKUs for dyslipidaemia management. Latest addition to Cardio-Metabolic franchise.
• Glovadip (Valsartan + Amlodipine) Combination antihypertensive medication combining Valsartan and Amlodipine for blood pressure management.
• Uriout (Febuxostat) Febuxostat xanthine oxidase inhibitor for chronic gout management.
• GP+ Hand Sanitizer UAE-made hand rub sanitizer containing 75% Isopropyl alcohol, approved by Dubai Municipality and manufactured according to WHO guidelines. Available in 100ml and 250ml spray bottles.
• GP+ Surgical Face Masks UAE-made surgical disposable face masks with high-quality melt blown filter offering highest filtration rate, produced under UV sterilization at GMP-compliant facilities.
• Sartan / Emisartan (Losartan) and Sartan H / Emisartan H (Losartan/HCT) Losartan angiotensin receptor blocker for hypertension management, available in 50mg and 100mg tablets, also combined with hydrochlorothiazide (HCT) for enhanced blood pressure control.
• Emivanz (Metformin + Glibenclamide) and Emipride (Glimepiride) Combination antidiabetic medications for Type 2 diabetes management, including Metformin HCl + Glibenclamide combination and Glimepiride sulfonylurea in 1mg, 2mg, and 3mg tablets.
• Allergy product line (Glozal, Emilora/Glora, Glotrizine, Gloditen, EzeAir) Anti-histamine product line including Levocetirizine, Loratadine, Cetirizine, Ketotifen, and Montelukast for allergy and asthma treatment in tablets, chewable tablets, and syrup forms.
• Emilok (Omeprazole) and Zaeer/Glofel (Tadalafil) Other therapeutic products including Omeprazole proton pump inhibitor in 20mg and 40mg capsules for acid-related disorders, and Tadalafil in 5mg and 20mg tablets for erectile dysfunction.

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core, major and minor.

• ZIM Laboratories (India)coreTechnology or Integration · 7 April 2025Partnership to bring EU-certified Oral Dispersible Film (ODF) technology to UAE and the Middle East. The ODF technology offers thin, fast-dissolving strips that melt in the mouth without water, ideal for children, elderly patients, and those with swallowing difficulties. The agreement was signed at AIM Congress 2025 and witnessed by H.E. Dr. Thani bin Ahmed Al Zeyoudi, Minister of State for Foreign Trade. Globalpharma is establishing a dedicated production line with a growing portfolio of ten ODF products.
• Al Fujairah Healing CompanycoreStrategic or Co-development Partner · 21 December 2021Strategic collaboration for the development, manufacturing, marketing, promotion and distribution of MG21 herbal anti-inflammatory medicine across the Middle East. Globalpharma inaugurated the first MOHAP approved herbal manufacturing line at its Dubai Investments Park facility. Al Fujairah Healing Company selected Globalpharma to produce and distribute MG21, which is estimated to yield an annual production capacity of around half million capsules.
• AlphamedmajorChannel Partner/ Reseller/ DistributorDistribution agreement signed with Alphamed, one of the leading local suppliers in the UAE, to ensure availability of MG21 herbal medicine in the majority of pharmacies before the end of the launch year.
• WasfatymajorChannel Partner/ Reseller/ DistributorStrategic partnership in Saudi Arabia for market access and distribution of Globalpharma products, contributing to the company's remarkable 139.5% year-over-year sales growth in the Saudi market.
• Emirates Red CrescentminorOthersHumanitarian partnership for earthquake relief efforts. Globalpharma supplied more than 144,000 packs of generic medicines including anti-inflammatories, analgesics, antiseptics, sanitisers, food supplements and anti-infectives to victims in Turkey and Syria in collaboration with Emirates Red Crescent.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Julphar (Gulf Pharmaceutical Industries): UAE-headquartered generic pharmaceutical manufacturer with broad MENA distribution, multi-therapeutic portfolio, and similar B2B/tender GTM. Closest direct competitor to Globalpharma in the UAE generics landscape.
• Neopharma: Abu Dhabi-based generic pharmaceutical manufacturer with manufacturing facilities in the UAE, India, and other emerging markets. Competes head-to-head with Globalpharma across GCC tenders and lifestyle disease therapeutics.
• SPIMACO Addwaeih: Saudi-listed generic pharmaceutical manufacturer with manufacturing in KSA and a strong Wasfaty/government tender presence — a direct peer competing for the same Saudi contracts driving Globalpharma's recent growth.
• Tabuk Pharmaceuticals: Saudi Arabia-based pharmaceutical company with branded generics, biosimilars, and specialty portfolio across MENA. Competes with Globalpharma in cardiovascular, anti-infectives, and CNS categories throughout the GCC.
• Hikma Pharmaceuticals: Jordan-headquartered global generic pharmaceutical manufacturer with strong MENA footprint and growing injectables/specialty franchise. The largest MENA-rooted generics peer and a benchmark for Globalpharma's regional ambitions.

Regional players

• EIPICO (Egyptian International Pharmaceutical Industries): Egypt-based generic pharmaceutical manufacturer with large domestic share and exports to GCC/Africa. Adjacent regional peer competing for the same African and Arab League tender markets Globalpharma targets.

Emerging players

• Aurobindo Pharma: Indian-based global generic manufacturer with extensive API and finished dosage manufacturing, increasingly competing in MENA tenders on price. A cost-competitive threat to Globalpharma's commodity generic portfolio.
• Cipla: Indian-headquartered global generic and specialty pharmaceutical manufacturer with established presence in Africa and growing Middle East footprint. Competes with Globalpharma across respiratory, cardiovascular, and anti-infective categories.
• Sun Pharmaceutical Industries: One of the largest Indian generic pharmaceutical companies with global manufacturing and distribution. Competes for MENA tenders and emerging-market share with Globalpharma across chronic disease therapies.

Broad incumbents

• Sanofi (MENA operations): Global pharmaceutical major with significant MENA manufacturing and commercial operations across branded specialty and generics. Serves as a broader benchmark for cardiovascular and metabolic portfolio breadth that Globalpharma is expanding into.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/GlobalpharmaAE
• Facebookfacebook.com/GlobalpharmaAE
• LinkedInlinkedin.com/company/global-pharma-llc

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Globalpharma